US 11,865,343 B2
Methods for treating post-traumatic stress disorder in patients via renal neuromodulation
Marcia Gallagher, Galway (IE); and Douglas A. Hettrick, Andover, MN (US)
Assigned to Medtronic Ireland Manufacturing Unlimited Company, Dublin (IE)
Filed by Medtronic Ireland Manufacturing Unlimited Company, Dublin (IE)
Filed on Nov. 1, 2021, as Appl. No. 17/516,322.
Application 17/516,322 is a continuation of application No. 16/026,344, filed on Jul. 3, 2018, granted, now 11,160,982.
Claims priority of provisional application 62/570,597, filed on Oct. 10, 2017.
Claims priority of provisional application 62/528,867, filed on Jul. 5, 2017.
Prior Publication US 2022/0054840 A1, Feb. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 1/36 (2006.01); A61B 18/02 (2006.01); A61N 1/05 (2006.01); A61B 18/04 (2006.01); A61N 7/00 (2006.01); A61B 18/18 (2006.01); A61N 2/00 (2006.01); A61B 18/00 (2006.01); A61B 18/08 (2006.01); A61B 18/22 (2006.01)
CPC A61N 1/36096 (2013.01) [A61B 18/02 (2013.01); A61N 1/0551 (2013.01); A61B 18/04 (2013.01); A61B 18/08 (2013.01); A61B 18/18 (2013.01); A61B 18/22 (2013.01); A61B 2018/0022 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00511 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00666 (2013.01); A61B 2018/00791 (2013.01); A61B 2018/00875 (2013.01); A61B 2018/0212 (2013.01); A61N 2/006 (2013.01); A61N 7/00 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method comprising:
prior to a patient experiencing a potential traumatic event, assessing the patient for risk of developing post-traumatic stress disorder (PTSD) in response to experiencing the potential traumatic event;
identifying the patient as being at risk for developing PTSD from experiencing the potential traumatic event; and
in response to identifying the patient as being at risk for developing PTSD from experiencing the potential traumatic event, executing a renal denervation procedure to reduce the risk associated with developing PTSD, the renal denervation procedure comprising:
intravascularly positioning a catheter carrying a neuromodulation assembly adjacent to a renal sympathetic nerve in the patient;
delivering energy to the renal sympathetic nerve via the neuromodulation assembly to at least partially ablate the renal sympathetic nerve to attenuate neural traffic along the renal sympathetic nerve; and
removing the catheter and the neuromodulation assembly from the patient after treatment.